Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
CRISPR Therapeutics AG Logo

ARKG Holdings of CRISPR Therapeutics (CRSP) - Updated Daily

Date
Direction
Shares
Fund Weight
Fund
June 14, 2022
BUY2.396k0.0062%ARKG
June 13, 2022
BUY20.059k0.0477%ARKG
March 1, 2022
BUY33.671k0.0497%ARKG
January 20, 2022
BUY61.494k0.1033%ARKG
January 5, 2022
BUY9.800k0.0137%ARKG

Key Statistics

🕵🏼Found In🏷Last Price
ARKGARKK$65.26
⚖️Weighting🧢Market Cap
4.24%$5.09b
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
5343.49
🏋️‍♀️Weight Rank Across All Funds🌏Country
10🇨🇭Switzerland
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$70.012.15%
Description
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Website
www.crisprtx.com